Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection
The data clearly show the potential usability of AGR3 and AGR2 as biomarkers for blood-based early detection of human breast cancer. Expand
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
This large-scale, single-cell atlas deepens the understanding of breast tumor ecosystems and suggests that ecosystem-based patient classification will facilitate identification of individuals for precision medicine approaches targeting the tumor and its immunoenvironment. Expand
Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening
Tumor-specific methylation of the three-gene panel (ITIH5, DKK3, and RASSF1A) might be a valuable biomarker for the early detection of breast cancer. Expand
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer
Silencing of BCAT1 in an orthotopic triple-negative xenograft model resulted in a massive reduction of tumor volume in vivo, supporting the findings thatBCAT1 is necessary for the growth of hormone-independent breast tumors. Expand
AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
The data suggest that AKT1E17K is the most likely disease driver in certain breast cancer patients and blood-based mutation detection is achievable in advanced-stage disease, underpin the need for a further enhanced-precision medicine paradigm in the treatment of breast cancer. Expand
Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
- H. Gevensleben, U. Göhring, +16 authors T. Anzeneder
- International journal of molecular medicine
- 1 December 2010
In this German study population, MammaPrint would have resulted in altered treatment advice for adjuvant systemic therapy in 40% of patients, and TargetPrint presented high concordance for ER, PR and Her2 with IHC and FISH/CISH analysis. Expand
SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection
Although liquid biopsy remains challenging, a combination of SPAG6, NKX2-6, ITIH5 and PER1 (SNiPER) provides a promising tool for blood-based breast cancer detection. Expand
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
The results suggest that ERα and ERRα cooperate to promote endocrine resistance, and they provide a rationale for the exploration of ERR α as a candidate drug target to treat endocrine-resistant breast cancer. Expand
The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.
- E. Peters, T. Anzeneder, +4 authors A. Waldmann
- Deutsches Arzteblatt international
- 31 August 2015
The cause of these age-related differences in treatment is unclear, but it cannot be determined whether concomitant disease, the older patients' individual decisions, or other factors were responsible for their not receiving treatment as often as the younger patients did. Expand
Bisphosphonates and their Role in Therapy for Breast Cancer - Results from the PATH Biobank.
- Eva-Maria Fick, T. Anzeneder, A. Katalinic, A. Waldmann
- Geburtshilfe und Frauenheilkunde
- 1 May 2013
In the PATH collective, bisphosphonates were employed above all for the treatment of (tumour therapy-induced) osteoporosis and bony metastases and the development (and use) of standardised, validated questionnaires to record the indications for and frequency of use of bisph phosphonate therapy is recommended. Expand